Regeneron Pharmaceuticals is a biotechnology company known for inventing its medicines internally through proprietary technologies including VelocImmune mice that produce fully human antibodies. Its two flagship franchises are Eylea and higher-dose Eylea HD for retinal diseases, facing biosimilar pressure, and Dupixent, the immunology blockbuster partnered with Sanofi that continues rapid growth across atopic dermatitis, asthma, COPD, and other indications. The oncology portfolio includes Libtayo and expanding bispecific antibodies Lynozyfic, odronextamab, and others, while the pipeline spans obesity combinations, genetic medicines with Alnylam and Intellia partnerships, and allergy. The Regeneron Genetics Center runs one of the world's largest human sequencing efforts to inform target discovery. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron is headquartered in Tarrytown, New York.

Interest Coverage

Beneish M-Score

Financial Strength

Altman Z-Score

Asset Growth

Insider Sell

Operating Margin %

PB Ratio

PE Ratio

Price

PS Ratio

Regeneron Pharmaceuticals Inc